JP2021502986A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502986A5 JP2021502986A5 JP2020526527A JP2020526527A JP2021502986A5 JP 2021502986 A5 JP2021502986 A5 JP 2021502986A5 JP 2020526527 A JP2020526527 A JP 2020526527A JP 2020526527 A JP2020526527 A JP 2020526527A JP 2021502986 A5 JP2021502986 A5 JP 2021502986A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- disease
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 28
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000004452 carbocyclyl group Chemical group 0.000 claims 5
- 208000035473 Communicable disease Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 3
- 230000002519 immonomodulatory effect Effects 0.000 claims 3
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 206010017533 Fungal infection Diseases 0.000 claims 2
- 206010062207 Mycobacterial infection Diseases 0.000 claims 2
- 208000031888 Mycoses Diseases 0.000 claims 2
- 208000030852 Parasitic disease Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 230000036281 parasite infection Effects 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 241000228212 Aspergillus Species 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000228405 Blastomyces dermatitidis Species 0.000 claims 1
- 241000588807 Bordetella Species 0.000 claims 1
- 241000588832 Bordetella pertussis Species 0.000 claims 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008631 Cholera Diseases 0.000 claims 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims 1
- 206010011732 Cyst Diseases 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 208000010772 Dog disease Diseases 0.000 claims 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 241000228404 Histoplasma capsulatum Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 201000005807 Japanese encephalitis Diseases 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 201000005505 Measles Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 241001149963 Sporothrix schenckii Species 0.000 claims 1
- 241000295644 Staphylococcaceae Species 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 206010043376 Tetanus Diseases 0.000 claims 1
- 208000037063 Thinness Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 241000607598 Vibrio Species 0.000 claims 1
- 208000003152 Yellow Fever Diseases 0.000 claims 1
- 241000607734 Yersinia <bacteria> Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003610 charcoal Substances 0.000 claims 1
- 238000011284 combination treatment Methods 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 229940045808 haemophilus influenzae type b Drugs 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000018773 low birth weight Diseases 0.000 claims 1
- 231100000533 low birth weight Toxicity 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 230000003990 molecular pathway Effects 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 206010048828 underweight Diseases 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 0 Cc1c(*)cccc1 Chemical compound Cc1c(*)cccc1 0.000 description 2
- YTZKOQUCBOVLHL-UHFFFAOYSA-N CC(C)(C)c1ccccc1 Chemical compound CC(C)(C)c1ccccc1 YTZKOQUCBOVLHL-UHFFFAOYSA-N 0.000 description 1
- RNDNSYIPLPAXAZ-UHFFFAOYSA-N CC(CO)c1ccccc1 Chemical compound CC(CO)c1ccccc1 RNDNSYIPLPAXAZ-UHFFFAOYSA-N 0.000 description 1
- ZJMWRROPUADPEA-UHFFFAOYSA-N CCC(C)c1ccccc1 Chemical compound CCC(C)c1ccccc1 ZJMWRROPUADPEA-UHFFFAOYSA-N 0.000 description 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N CCc1ccccc1 Chemical compound CCc1ccccc1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
- WGBKESSICUWUHH-UHFFFAOYSA-N Cc(c(C(F)(F)F)c1)ccc1Cl Chemical compound Cc(c(C(F)(F)F)c1)ccc1Cl WGBKESSICUWUHH-UHFFFAOYSA-N 0.000 description 1
- XXLNKGOPDHIOCS-UHFFFAOYSA-N Cc(c(C(F)(F)F)c1)ccc1F Chemical compound Cc(c(C(F)(F)F)c1)ccc1F XXLNKGOPDHIOCS-UHFFFAOYSA-N 0.000 description 1
- YUCGIKTVAIPINQ-UHFFFAOYSA-N Cc(c(C(F)(F)F)ccc1)c1F Chemical compound Cc(c(C(F)(F)F)ccc1)c1F YUCGIKTVAIPINQ-UHFFFAOYSA-N 0.000 description 1
- FXDCXDDQWOBPJF-UHFFFAOYSA-N Cc(c(NC(c(cc1)c(C(F)(F)F)cc1Cl)=O)c1)ccc1-c1c[n](cc(cn2)F)c2n1 Chemical compound Cc(c(NC(c(cc1)c(C(F)(F)F)cc1Cl)=O)c1)ccc1-c1c[n](cc(cn2)F)c2n1 FXDCXDDQWOBPJF-UHFFFAOYSA-N 0.000 description 1
- IUEMCRJKUUXXTB-UHFFFAOYSA-N Cc(c(NC(c(cc1)c(C)cc1OC)=O)c1)ccc1-c1c[n](cccn2)c2n1 Chemical compound Cc(c(NC(c(cc1)c(C)cc1OC)=O)c1)ccc1-c1c[n](cccn2)c2n1 IUEMCRJKUUXXTB-UHFFFAOYSA-N 0.000 description 1
- BHZDWRCUUDBJIT-UHFFFAOYSA-N Cc(c(NC(c1c(C(F)(F)F)cc(C[F]c(cn2)c[n]3c2nc(-c2cc(NC(c4c(C(F)(F)F)cccc4F)=O)c(C)cc2)c3)cc1)=O)c1)ccc1-c1c[n](cc(cn2)F)c2n1 Chemical compound Cc(c(NC(c1c(C(F)(F)F)cc(C[F]c(cn2)c[n]3c2nc(-c2cc(NC(c4c(C(F)(F)F)cccc4F)=O)c(C)cc2)c3)cc1)=O)c1)ccc1-c1c[n](cc(cn2)F)c2n1 BHZDWRCUUDBJIT-UHFFFAOYSA-N 0.000 description 1
- LVUBSVWMOWKPDJ-UHFFFAOYSA-N Cc(cc1)c(C)cc1OC Chemical compound Cc(cc1)c(C)cc1OC LVUBSVWMOWKPDJ-UHFFFAOYSA-N 0.000 description 1
- FIAPVMGNKSVLMB-UHFFFAOYSA-N Cc(ccc(-c1c[n](cc(cn2)F)c2n1)c1)c1NC(C(CO)c1ccccc1)=O Chemical compound Cc(ccc(-c1c[n](cc(cn2)F)c2n1)c1)c1NC(C(CO)c1ccccc1)=O FIAPVMGNKSVLMB-UHFFFAOYSA-N 0.000 description 1
- WEMCENUBGNCHEZ-UHFFFAOYSA-N Cc(ccc(-c1c[n](cc(cn2)F)c2n1)c1)c1NC(c(cc1)c(C(F)(F)F)cc1F)=O Chemical compound Cc(ccc(-c1c[n](cc(cn2)F)c2n1)c1)c1NC(c(cc1)c(C(F)(F)F)cc1F)=O WEMCENUBGNCHEZ-UHFFFAOYSA-N 0.000 description 1
- PHDGXZAKUYYNHA-UHFFFAOYSA-N Cc(ccc(-c1c[n](cc(cn2)F)c2n1)c1)c1NC(c(cc1)c(C)cc1OC)=O Chemical compound Cc(ccc(-c1c[n](cc(cn2)F)c2n1)c1)c1NC(c(cc1)c(C)cc1OC)=O PHDGXZAKUYYNHA-UHFFFAOYSA-N 0.000 description 1
- LDUBKHCJFRCYHY-UHFFFAOYSA-N Cc(ccc(-c1c[n](cccn2)c2n1)c1)c1NC(C(CO)c(cc1)ccc1-c1c(C)c(C(Nc2cc(-c3c[n](cccn4)c4n3)ccc2C)=O)cc(OC)c1)=O Chemical compound Cc(ccc(-c1c[n](cccn2)c2n1)c1)c1NC(C(CO)c(cc1)ccc1-c1c(C)c(C(Nc2cc(-c3c[n](cccn4)c4n3)ccc2C)=O)cc(OC)c1)=O LDUBKHCJFRCYHY-UHFFFAOYSA-N 0.000 description 1
- KXPHBBLQAOIDJO-UHFFFAOYSA-N Cc(ccc(OC)c1)c1C(Nc1cc(-c2c[n](cc(cn3)F)c3n2)ccc1C)=O Chemical compound Cc(ccc(OC)c1)c1C(Nc1cc(-c2c[n](cc(cn3)F)c3n2)ccc1C)=O KXPHBBLQAOIDJO-UHFFFAOYSA-N 0.000 description 1
- QSSXJPIWXQTSIX-UHFFFAOYSA-N Cc(cccc1)c1Br Chemical compound Cc(cccc1)c1Br QSSXJPIWXQTSIX-UHFFFAOYSA-N 0.000 description 1
- XBUKSKTZQURUDT-UHFFFAOYSA-N Cc1c(C(F)(F)F)ccc(F)c1 Chemical compound Cc1c(C(F)(F)F)ccc(F)c1 XBUKSKTZQURUDT-UHFFFAOYSA-N 0.000 description 1
- RIKQFBGCNQAHBO-UHFFFAOYSA-N Cc1ccc(C)c(C(F)(F)F)c1 Chemical compound Cc1ccc(C)c(C(F)(F)F)c1 RIKQFBGCNQAHBO-UHFFFAOYSA-N 0.000 description 1
- DVFVNJHIVAPTMS-UHFFFAOYSA-N Cc1ccccc1C(F)(F)F Chemical compound Cc1ccccc1C(F)(F)F DVFVNJHIVAPTMS-UHFFFAOYSA-N 0.000 description 1
- IBSQPLPBRSHTTG-UHFFFAOYSA-N Cc1ccccc1Cl Chemical compound Cc1ccccc1Cl IBSQPLPBRSHTTG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762586124P | 2017-11-14 | 2017-11-14 | |
| US62/586,124 | 2017-11-14 | ||
| PCT/US2018/061117 WO2019099564A1 (en) | 2017-11-14 | 2018-11-14 | Novel imidazopyrimidine compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502986A JP2021502986A (ja) | 2021-02-04 |
| JP2021502986A5 true JP2021502986A5 (https=) | 2022-01-04 |
| JP7304855B2 JP7304855B2 (ja) | 2023-07-07 |
Family
ID=66540372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526527A Active JP7304855B2 (ja) | 2017-11-14 | 2018-11-14 | 新規イミダゾピリミジン化合物およびそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11673891B2 (https=) |
| EP (1) | EP3709998B8 (https=) |
| JP (1) | JP7304855B2 (https=) |
| KR (1) | KR102740831B1 (https=) |
| CN (1) | CN111936136B (https=) |
| WO (1) | WO2019099564A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS65914B1 (sr) | 2017-04-18 | 2024-10-31 | Lilly Co Eli | Fenil-2-hidroksi-acetilamino-2-metil-fenil jedinjenja |
| EP3710007A4 (en) * | 2017-11-14 | 2021-12-15 | Children's Medical Center Corporation | USE OF IMIDAZOPYRIMIDINE TO MODULATE HUMAN IMMUNE RESPONSE |
| KR102740831B1 (ko) | 2017-11-14 | 2024-12-11 | 칠드런'즈 메디컬 센터 코포레이션 | 신규 이미다조피리미딘 화합물 및 그의 용도 |
| CN114585606A (zh) | 2019-08-29 | 2022-06-03 | 希伯塞尔股份有限公司 | 抑制perk的化合物 |
| WO2021231784A1 (en) * | 2020-05-13 | 2021-11-18 | Hibercell, Inc. | Perk inhibiting imidazolopyrazine compounds |
| WO2024151501A1 (en) * | 2023-01-09 | 2024-07-18 | The Children's Medical Center Corporation | Novel imidazopyrimidine compound and uses thereof |
| WO2025151620A1 (en) * | 2024-01-10 | 2025-07-17 | The Children's Medical Center Corporation | Functionalized imidazopyrimidine compounds and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69524598T2 (de) | 1994-06-20 | 2002-07-11 | Takeda Chemical Industries, Ltd. | Kondensierte imidazolderivate, ihre herstellung und verwendung |
| ES2237470T3 (es) * | 1999-11-10 | 2005-08-01 | Ortho-Mcneil Pharmaceutical, Inc. | 2-aril-3-(heteroaril)-imidazo(1,2-alfa)pirimidinas sustituidas; y composiciones farmaceuticas y procedimientos asociados. |
| JP2001302667A (ja) | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| EP1294723A1 (en) | 2000-05-24 | 2003-03-26 | MERCK SHARP & DOHME LTD. | 3-phenyl-imidazo-pyrimidine derivatives as ligands for gaba receptors |
| GB0128499D0 (en) | 2001-11-28 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
| ES2328047T3 (es) | 2004-03-19 | 2009-11-06 | Warner-Lambert Company Llc | Derivados de imidazopiridina e imidazopirimidina como agentes antibacterianos. |
| BRPI0513811A (pt) | 2004-07-27 | 2008-07-15 | Gilead Sciences Inc | imidazo [4,5-d] pirimidinas, seus usos e processos de preparação |
| US20080193468A1 (en) | 2004-09-08 | 2008-08-14 | Children's Medical Center Corporation | Method for Stimulating the Immune Response of Newborns |
| DK1910384T3 (da) | 2005-08-04 | 2012-12-17 | Sirtris Pharmaceuticals Inc | Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser |
| US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| EP1955077B1 (en) * | 2005-12-02 | 2012-06-13 | Sirtris Pharmaceuticals, Inc. | Mass spectrometry assays for acetyltransferase/deacetylase activity |
| WO2008027812A2 (en) | 2006-08-28 | 2008-03-06 | Forest Laboratories Holdings Limited | Imidazopyridine and imidazopyrimidine derivatives |
| RS54510B1 (sr) | 2006-11-22 | 2016-06-30 | Incyte Holdings Corporation | Imidazotriazini i imidazopirimidini kao inhibitori kinaze |
| RU2364597C1 (ru) | 2007-12-14 | 2009-08-20 | Андрей Александрович Иващенко | ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ |
| EP2103614A1 (en) | 2008-03-18 | 2009-09-23 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators |
| US20100168084A1 (en) | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
| FR2933982A1 (fr) | 2008-07-18 | 2010-01-22 | Sanofi Aventis | Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| JP5694345B2 (ja) | 2009-10-22 | 2015-04-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｏｌｌ様受容体の調節因子 |
| TWI617559B (zh) * | 2010-12-22 | 2018-03-11 | 江蘇恆瑞醫藥股份有限公司 | ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物 |
| GB201120000D0 (en) | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
| CN103570625A (zh) | 2012-07-19 | 2014-02-12 | 南京英派药业有限公司 | N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 |
| US9695212B2 (en) | 2012-12-13 | 2017-07-04 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| JP6356160B2 (ja) | 2013-02-25 | 2018-07-11 | ザ スクリプス リサーチ インスティテュート | ネオセプチン：低分子アジュバント |
| EP2964648B1 (en) | 2013-03-05 | 2016-11-16 | Merck Patent GmbH | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
| WO2014151729A1 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| US9296754B2 (en) | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| CN103467590B (zh) | 2013-09-02 | 2016-04-13 | 深圳大学 | 生物偶联体、制备其的嘌呤类化合物、合成方法、药用制剂以及其在免疫调节中的应用 |
| GB201321736D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| BR112016026951B1 (pt) | 2014-06-25 | 2022-09-20 | F. Hoffmann-La Roche Ag | Imidazo[1,2-a]pirazin-1-il-benzamida, seu uso, e composições farmacêuticas |
| TW201643143A (zh) | 2015-03-13 | 2016-12-16 | 國立大學法人北海道大學 | 抑制氧化壓迫引發的神經細胞死亡之化合物 |
| CN107849084B (zh) | 2015-12-03 | 2021-09-14 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为sting调节剂的环状嘌呤二核苷酸 |
| KR102740831B1 (ko) | 2017-11-14 | 2024-12-11 | 칠드런'즈 메디컬 센터 코포레이션 | 신규 이미다조피리미딘 화합물 및 그의 용도 |
| EP3710007A4 (en) | 2017-11-14 | 2021-12-15 | Children's Medical Center Corporation | USE OF IMIDAZOPYRIMIDINE TO MODULATE HUMAN IMMUNE RESPONSE |
-
2018
- 2018-11-14 KR KR1020207016955A patent/KR102740831B1/ko active Active
- 2018-11-14 CN CN201880084871.2A patent/CN111936136B/zh active Active
- 2018-11-14 US US16/764,171 patent/US11673891B2/en active Active
- 2018-11-14 JP JP2020526527A patent/JP7304855B2/ja active Active
- 2018-11-14 WO PCT/US2018/061117 patent/WO2019099564A1/en not_active Ceased
- 2018-11-14 EP EP18879326.9A patent/EP3709998B8/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502986A5 (https=) | ||
| JP3732506B2 (ja) | ワクチンアジュバント | |
| RU2018137389A (ru) | Гетероциклические амиды, полезные в качестве модуляторов | |
| Lim et al. | The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease | |
| JP2017533925A5 (https=) | ||
| JP2021530442A5 (https=) | ||
| SI2895174T1 (en) | The prodrugs of the amino quinazoline kinase inhibitor | |
| JP2021525787A5 (https=) | ||
| US9884032B2 (en) | Esters of short chains fatty acids for use in the treatment of immunogenic disorders | |
| RU2007119390A (ru) | Соединения 4-метоксиметил-пирролидин-2-карбоновой кислоты и их производные - ингибиторы вируса гепатита с | |
| JP2016509051A5 (https=) | ||
| JP2021501791A5 (https=) | ||
| Bowen et al. | Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague | |
| US20220184092A1 (en) | Anti-viral activity of vps34 inhibitors | |
| US20220184077A1 (en) | Anti-viral activity of vps34 inhibitors | |
| US20220184050A1 (en) | Anti-viral activity of vps34 inhibitors | |
| CA3199995A1 (en) | Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection | |
| JP4313847B2 (ja) | 免疫賦活性イノシン一リン酸の５’−ヌクレオチダーゼ抵抗性誘導体およびその使用 | |
| JP2018509452A5 (https=) | ||
| JP2021502988A5 (https=) | ||
| MX2019012620A (es) | Composiciones de vacunas. | |
| Lloren et al. | Salmonella-mediated oral delivery of multiple-target vaccine constructs with conserved and variable regions of SARS-CoV-2 protect against the Delta and Omicron variants in hamster | |
| JP2022513001A5 (https=) | ||
| EA201401044A1 (ru) | Модифицированный вирус болезни марека и вакцины на его основе | |
| ES2549366B1 (es) | TRIPLE MUTANTE DEL COMPLEJO MYCOBACTERIUM TUBERCULOSIS erp-, phoP- y DIM- |